Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. ABBV
4. IBM
5. META
6. MU
7. ACN
8. NVDA
9. FDX
10. BLZE

Go back to Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients

Eli Lilly (LLY) PT Lowered to $305 at BMO Capital

February 4, 2022 6:55 AM EST

BMO Capital analyst Evan David Seigerman lowered the price target on Eli Lilly (NYSE: LLY) to $305.00 (from $310.00) while maintaining an Outperform rating.

The analyst commented, "Donanemab concerns overshadow a solid quarter and set up into 2022. Despite solid set of 4Q21 results and reiterated... More

Eli Lilly & Co. (LLY) Tops Q4 EPS by 34c, Revenue Beats, Offers Guidance

February 3, 2022 6:26 AM EST

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.49, $0.34 better than the analyst estimate of $2.15. Revenue for the quarter came in at $8 billion versus the consensus estimate of $6.74 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2022 EPS of $8.50-$8.65, versus the... More